This is an editorial. The purpose is to point out the limits of the empirical literature linking launch delays of new drugs with the regulation of entry. We find four main problems related to the main conclusions of the literature. We think that these limits should be aknowledged in the international debate on the regulation of drugs approvals.

Should we really worry about "launch delays" in OECD countries?

GHISLANDI, SIMONE
2007

Abstract

This is an editorial. The purpose is to point out the limits of the empirical literature linking launch delays of new drugs with the regulation of entry. We find four main problems related to the main conclusions of the literature. We think that these limits should be aknowledged in the international debate on the regulation of drugs approvals.
2007
Garattini, L; Ghislandi, Simone
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11565/40126
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact